QCLS Q/C TECHNOLOGIES, INC.
Nasdaq · SEC CIK 1321834 · EDGAR
- Bought, last 12 months
- $5,522 1 purchases by 1 insiders
- Sold, last 12 months
- $0 0 sales by 0 insiders
- Filings on record
- 45 since 2021-10-15, latest 2026-05-14 17:33
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Voss Chelsea Sierra | Dir | $5,522 | — |
| Friscia Stephen | Dir | — | — |
| Glass Mitchell | Dir, Chief Medical Off | — | — |
| Bernstein Bruce | Dir | — | — |
| RAUCH GARY M | VP of Fin | — | — |
| White Billy Joe | Dir | — | — |
| Silverman Joshua | Executive COB, Dir | — | — |
Transactions 19
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2026-05-14 17:33 | 2026-03-30 | QCLS | Voss Chelsea Sierra | Dir | P - Purchase | $3.15 | +1,753 | 61.6K | +3% | +$5,522 |
| D | 2026-04-15 18:29 | 2026-04-13 | QCLS | Silverman Joshua | Executive COB, Dir | A - Grant | $0.00 | +162.2K | 262.2K | +162% | $0 |
| DM | 2026-01-30 | 2026-01-16 | QCLS | Voss Chelsea Sierra | Dir | A - Grant | $0.00 | +237.5K | 214.9K | New | $0 |
| 2025-11-17 | 2025-11-14 | QCLS | Glass Mitchell | Dir, Chief Medical Off | A - Grant | $0.00 | +11.4K | 12.5K | +1,057% | $0 | |
| 2025-11-17 | 2025-11-14 | QCLS | White Billy Joe | Dir | A - Grant | $0.00 | +22.8K | 25.0K | +1,045% | $0 | |
| 2025-11-14 | 2025-11-14 | QCLS | RAUCH GARY M | VP of Fin | A - Grant | $0.00 | +11.4K | 12.5K | +1,057% | $0 | |
| 2025-11-14 | 2025-11-14 | QCLS | Bernstein Bruce | Dir | A - Grant | $0.00 | +25.0K | 25.0K | New | $0 | |
| 2025-11-14 | 2025-11-14 | QCLS | Silverman Joshua | Executive COB, Dir | A - Grant | $0.00 | +91.4K | 100.0K | +1,053% | $0 | |
| 2025-11-14 | 2025-11-14 | QCLS | Friscia Stephen | Dir | A - Grant | $0.00 | +22.8K | 25.0K | +1,057% | $0 | |
| 2025-10-06 | 2025-10-03 | QCLS | White Billy Joe | Dir | A - Grant | $0.00 | +2,161 | 2,185 | +9,004% | $0 | |
| 2025-10-06 | 2025-10-03 | QCLS | RAUCH GARY M | VP of Fin | A - Grant | $0.00 | +1,080 | 1,080 | New | $0 | |
| 2025-10-06 | 2025-10-03 | QCLS | Friscia Stephen | Dir | A - Grant | $0.00 | +2,161 | 2,161 | New | $0 | |
| 2025-10-06 | 2025-10-03 | QCLS | Silverman Joshua | Executive COB, Dir | A - Grant | $0.00 | +8,644 | 8,673 | +29,807% | $0 | |
| 2025-10-06 | 2025-10-03 | QCLS | Glass Mitchell | Dir, Chief Medical Off | A - Grant | $0.00 | +1,080 | 1,080 | New | $0 | |
| 2023-08-24 | 2023-08-24 | QCLS | Rivard Paul | CLO | P - Purchase | $1.11 | +150.0K | 400.0K | +60% | +$166.5K | |
| 2023-08-18 | 2023-08-17 | QCLS | Rivard Paul | CLO | P - Purchase | $1.12 | +25.0K | 250.0K | +11% | +$28.0K | |
| 2022-12-08 | 2022-12-08 | QCLS | Rivard Paul | GC, EVP of Ops | P - Purchase | $1.53 | +10.0K | 225.0K | +5% | +$15.3K | |
| M | 2021-11-29 | 2021-11-24+ | QCLS | Silverman Joshua | Dir | P - Purchase | $6.89 | +15.0K | 80.5K | +23% | +$103.3K |
| 2021-11-24 | 2021-11-23 | QCLS | Rivard Paul | GC, EVP of Ops | P - Purchase | $6.03 | +15.0K | 215.0K | +8% | +$90.5K |
Purchase Sale Sale after option exercise All abbreviations